Kim Y K, Lee H W, Son K H, Kwon B M, Jeong T S, Lee D H, Shin J, Seo Y, Kim S U, Bok S H
Bioproducts Research Group, Korea Research Institute of Bioscience & Biotechnology, KIST, Yusung , Korea.
J Antibiot (Tokyo). 1996 Jan;49(1):31-6. doi: 10.7164/antibiotics.49.31.
A new inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), designated GERI-BP002-A, was isolated from the culture broth of Aspergillus fumigatus F93 by acetone extraction, EtOAc extraction, SiO2 column chromatography and reverse phase HPLC. Spectroscopic analyses of the compound identified bis (2-hydroxy-3-tert-butyl-5-methylphenyl) methane as the structure and its molecular weight and formula to be 340 and C23H32O2, respectively. GERI-BP002-A inhibited ACAT activity by 50% at the concentration of 50 microM in an enzyme assay system using rat liver microsomes.
一种新型的酰基辅酶A：胆固醇酰基转移酶（ACAT）抑制剂，命名为GERI-BP002-A，通过丙酮萃取、乙酸乙酯萃取、硅胶柱色谱和反相高效液相色谱从烟曲霉F93的培养液中分离得到。对该化合物的光谱分析确定其结构为双（2-羟基-3-叔丁基-5-甲基苯基）甲烷，分子量为340，分子式为C23H32O2。在使用大鼠肝微粒体的酶分析系统中，GERI-BP002-A在浓度为50微摩尔时可抑制50%的ACAT活性。
